Bioage Labs Inc (BIOA)

$13.21 -0.37 (-2.72%)
Market Cap 486.91M
Revenue (ttm) 0.00
Net Income (ttm) -71.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 309,100
Avg Vol 503,912
Day's Range N/A - N/A
Shares Out 35.86M
Stochastic %K 72%
Beta 1.72
Analysts Sell
Price Target $12.00

Company Profile

BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the t...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 510 806 1445
Address:
1445A South 50th Street, Richmond, United States
TalkMarkets
TalkMarkets Dec. 23 at 10:03 PM
#Goldman's Small-Cap #Biotech Universe: The 2026 Catalyst Playbook For Investors $ABCL $BIOA $ALLO $GOSS $LYEL https://talkmarkets.com/content/stocks--equities/goldmans-small-cap-biotech-universe-the-2026-catalyst-playbook-for-investors?post=546436
1 · Reply
Maahai
Maahai Dec. 22 at 10:06 PM
$BIOA interested…
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 16 at 2:40 AM
$BIOA Share Price: $12.49 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $2.00 – $2.47 Target Zone: $3.32 – $4.06 Potential Upside: 57% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Dec. 9 at 9:34 PM
Stock Upgrades Today ​$OCUL $KMDA $LEGN $BIOA $NBIX Biotech stars breaking out https://stocksrunner.com/news/2025-12-09-stock-upgrades-today-show-top-picks
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 5:07 PM
Morgan Stanley updates rating for Bioage Labs ( $BIOA ) to Equal-Weight, target set at 5 → 12.
0 · Reply
xrpmoonbaby
xrpmoonbaby Dec. 6 at 1:25 AM
$BIOA fuck i sold at fucking 8
0 · Reply
DayTrade_4Life
DayTrade_4Life Dec. 4 at 7:17 PM
Results so far from Today's Watchlist (WL) and Alerts. Join us for Profits. We have Alerts, Watchlists, Swings, Education Resources, Scanners and News Feeds. $SMX: $70 to $118 (68%) 9:30 WL/Alert $QCLS: 4.75 to 7.95 (67%); 5.70 Breakout (39%) WL/Alert $PMCB: $1 to 1.46 (46%) WL/ Alert $PMI: 2.45 to 3.23 (31%) WL/Alert $BIOA: $10 to $11 (10%) Alert/WL Swing Play (not shown in image): QUBT up 18%.
0 · Reply
Dauphinoise
Dauphinoise Dec. 4 at 6:18 PM
$BIOA That better?
0 · Reply
vmst1
vmst1 Dec. 4 at 5:19 PM
$VTYX The $BIOA result for its BGE-102 NLRP3 inhibitor showed great promise through double blinded randomized and placebo controlled phase 1 study. it has two implications for VTYX; NLRP3 appears to be almost proven pathway both for CNS and peripheral targets. And there would be competition for VTYX down the years. Perhaps VTYX decision to delay its Phase 2 recurrent pericarditis study is part of strategy to gain edge through global extension studies? VTYX does have lead in NLRP3 pathway drugs and BIOA result yesterday should help overcome doubts about slightly diminished VTYX potential long term future due to recently announced delay. I don't think NLRP3 inhibition works for weight loss indication as shown by VTYX in phase 2, so BIOA studies might settle that pre-clinical theory in coming months.
0 · Reply
Crib
Crib Dec. 4 at 3:05 PM
$BIOA what is the news for this upside ?
0 · Reply
Latest News on BIOA
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Dec 4, 2025, 9:00 AM EST - 19 days ago

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:30 PM EST - 4 weeks ago

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

Nov 7, 2025, 9:00 AM EST - 6 weeks ago

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

Sep 15, 2025, 9:30 AM EDT - 3 months ago

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

BioAge Labs to Present at Upcoming Investor Conferences

Aug 20, 2025, 4:30 PM EDT - 4 months ago

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Aug 15, 2025, 9:00 AM EDT - 4 months ago

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 4:30 PM EDT - 4 months ago

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Jun 21, 2025, 6:00 PM EDT - 6 months ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

Jun 17, 2025, 9:00 AM EDT - 6 months ago

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 8 months ago

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Mar 20, 2025, 4:30 PM EDT - 9 months ago

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA

Mar 10, 2025, 9:30 PM EDT - 10 months ago

Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA

BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 10, 2025, 6:33 PM EDT - 10 months ago

BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman

Mar 7, 2025, 4:11 PM EST - 10 months ago

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO - Hagens Berman

Mar 6, 2025, 1:30 PM EST - 10 months ago

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO - Hagens Berman

BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 5, 2025, 3:45 PM EST - 10 months ago

BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman

Mar 3, 2025, 3:19 PM EST - 10 months ago

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman

BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)

Mar 2, 2025, 7:23 AM EST - 10 months ago

BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman

Mar 1, 2025, 6:00 PM EST - 10 months ago

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Feb 28, 2025, 3:30 PM EST - 10 months ago

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Feb 27, 2025, 9:24 AM EST - 10 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Investors in BioAge Labs, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

Feb 27, 2025, 5:45 AM EST - 10 months ago

Investors in BioAge Labs, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Feb 23, 2025, 9:24 AM EST - 10 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

BIOA SECURITIES NEWS: BioAge has been Sued for Securities Violations - Investors are Alerted to Contact BFA Law by March 10 Legal Deadline

Feb 21, 2025, 3:17 PM EST - 10 months ago

BIOA SECURITIES NEWS: BioAge has been Sued for Securities Violations - Investors are Alerted to Contact BFA Law by March 10 Legal Deadline

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

Feb 20, 2025, 4:30 PM EST - 10 months ago

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BioAge Labs Stock Alert - Investors of BioAge Encouraged to Contact Kehoe Law Firm, P.C. - BIOA

Feb 20, 2025, 9:30 AM EST - 10 months ago

BioAge Labs Stock Alert - Investors of BioAge Encouraged to Contact Kehoe Law Firm, P.C. - BIOA

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Feb 19, 2025, 11:16 AM EST - 10 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

TalkMarkets
TalkMarkets Dec. 23 at 10:03 PM
#Goldman's Small-Cap #Biotech Universe: The 2026 Catalyst Playbook For Investors $ABCL $BIOA $ALLO $GOSS $LYEL https://talkmarkets.com/content/stocks--equities/goldmans-small-cap-biotech-universe-the-2026-catalyst-playbook-for-investors?post=546436
1 · Reply
Maahai
Maahai Dec. 22 at 10:06 PM
$BIOA interested…
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 16 at 2:40 AM
$BIOA Share Price: $12.49 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $2.00 – $2.47 Target Zone: $3.32 – $4.06 Potential Upside: 57% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Dec. 9 at 9:34 PM
Stock Upgrades Today ​$OCUL $KMDA $LEGN $BIOA $NBIX Biotech stars breaking out https://stocksrunner.com/news/2025-12-09-stock-upgrades-today-show-top-picks
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 5:07 PM
Morgan Stanley updates rating for Bioage Labs ( $BIOA ) to Equal-Weight, target set at 5 → 12.
0 · Reply
xrpmoonbaby
xrpmoonbaby Dec. 6 at 1:25 AM
$BIOA fuck i sold at fucking 8
0 · Reply
DayTrade_4Life
DayTrade_4Life Dec. 4 at 7:17 PM
Results so far from Today's Watchlist (WL) and Alerts. Join us for Profits. We have Alerts, Watchlists, Swings, Education Resources, Scanners and News Feeds. $SMX: $70 to $118 (68%) 9:30 WL/Alert $QCLS: 4.75 to 7.95 (67%); 5.70 Breakout (39%) WL/Alert $PMCB: $1 to 1.46 (46%) WL/ Alert $PMI: 2.45 to 3.23 (31%) WL/Alert $BIOA: $10 to $11 (10%) Alert/WL Swing Play (not shown in image): QUBT up 18%.
0 · Reply
Dauphinoise
Dauphinoise Dec. 4 at 6:18 PM
$BIOA That better?
0 · Reply
vmst1
vmst1 Dec. 4 at 5:19 PM
$VTYX The $BIOA result for its BGE-102 NLRP3 inhibitor showed great promise through double blinded randomized and placebo controlled phase 1 study. it has two implications for VTYX; NLRP3 appears to be almost proven pathway both for CNS and peripheral targets. And there would be competition for VTYX down the years. Perhaps VTYX decision to delay its Phase 2 recurrent pericarditis study is part of strategy to gain edge through global extension studies? VTYX does have lead in NLRP3 pathway drugs and BIOA result yesterday should help overcome doubts about slightly diminished VTYX potential long term future due to recently announced delay. I don't think NLRP3 inhibition works for weight loss indication as shown by VTYX in phase 2, so BIOA studies might settle that pre-clinical theory in coming months.
0 · Reply
Crib
Crib Dec. 4 at 3:05 PM
$BIOA what is the news for this upside ?
0 · Reply
mebanks
mebanks Dec. 4 at 3:01 PM
$BIOA , thought this would run a bit more.
0 · Reply
www_larval_com
www_larval_com Dec. 4 at 2:42 PM
$BIOA 5%[17%] $KXIN 4%[-6%] $UPC 4%[15%] $SLMT -4%[-11%] $MBX 4%[-7%] most notable movement within the first minutes of trading.
1 · Reply
VERY_
VERY_ Nov. 23 at 12:38 PM
$BIOA $AUTL $RCKT $SPY lol wtf
0 · Reply
TalkMarkets
TalkMarkets Nov. 18 at 2:21 PM
Top 3 #Biotech #Stocks Capitalizing On The #AI Revolution $BIOA $NMRA $RLAY https://talkmarkets.com/content/stocks--equities/top-3-biotech-stocks-capitalizing-on-the-ai-revolution?post=538291
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 7 at 12:29 PM
$QURE $BIOA $DYN and $NPCE now. glta
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 3 at 6:14 PM
$QURE just need my $BIOA and $DYN puts to pay this big
0 · Reply
stockwitsuser2449
stockwitsuser2449 Oct. 28 at 6:06 PM
$LUNG whats a better short this or $BIOA ...don't hate just wondering opinions of shorts (also $DYN why not ...)
1 · Reply
stockwitsuser2449
stockwitsuser2449 Oct. 28 at 2:04 PM
$BIOA under 6 please :)
0 · Reply
Lunaris_2721
Lunaris_2721 Oct. 27 at 3:10 PM
$BIOA
0 · Reply
agamemnus
agamemnus Oct. 26 at 3:16 PM
$VTYX $BIOA One of these biotechs had amazing Phase 2 data. The other one has a drug in the same class without Phase 2 data.
1 · Reply
vmst1
vmst1 Oct. 26 at 2:49 AM
$BIOA With Ventyx positive results of it cardiometabolic drug in phase 2, BIOA had a "NLRP3 inhibitor success" rally for about 30%. Most missed the fact that Ventyx was also measuring weigh loss benefit, which was not observed in this phase 2 study but the company was enthusiastic about due to its preclinical results yielding weigh loss and lean mass relative maintenance. BIOA has the same opinion and its preclinical results purportedly for BGE 102 data showed powerful weight reduction both as monotherapy and in combo with GLP1. Ventyx CEO in the conference after the results did state that this study puts to rest the theory that NLRP3 pathway can reduce the weight. But VTYX was also measuring inflammation reduction so at least that link was proven. Problem with BIOA is that it classifies its study as Obesity drug. In fact with Ventyx its price should have gone down a bit as BGE 102 is the most advanced drug in the pipeline. Unless they have a differentiated drug in some specific way.
1 · Reply
josh77
josh77 Oct. 25 at 7:45 PM
$ICU Combined Recovery Path If SeaStar achieves positive adult trial data, strategic partnerships, and growing pediatric revenue, the stock could realistically return to the $5–$10 range over the next 12–18 months. $HKPD $BIOA $MRNO $TTRX
1 · Reply